Rheumatoid arthritis is usually treated with medications, and the therapeutic drugs with proven experience are divided into three main categories: adrenocorticotropic hormones (prednisone, dexamethasone), non-specific anti-inflammatory drugs (salicylic acid, indole) and anti-rheumatic drugs (methotrexate, tretinoin). These drugs have a certain effect of relieving the disease, but none of them can control the development of the disease and stop the deterioration of the disease, and they also have different degrees of toxic side effects, which can cause a variety of adverse reactions. The radiopharmaceutical technetium (99Tc) methylenediphosphonate (trade name “Yunke”) is a new drug for the treatment of rheumatoid arthritis, which is a chelate of the nuclear element technetium and methylenediphosphonate. Technetium does not exist in nature and can only be produced in nuclear reactors through a series of decays. Its role in the human body is to continuously scavenge free radicals in the body through the gain and loss of electrons outside the nucleus of elemental atoms, protect superoxide dismutase, inhibit the production of the immune-regulating factor interleukin, prevent the formation of immune complexes, and thus regulate the immune function of the human body. At the same time, Methylene Diphosphonate can inhibit the production of prostaglandins, reduce the activity of catabolic enzymes, prevent collagenase decomposition and destruction of cartilage tissue, and inhibit the vitality of osteoclasts. Together, they not only have anti-inflammatory and analgesic effect, but also have the function of immunosuppression, both the symptoms and the root cause, the total effective rate of the treatment can reach 80%, after the treatment of the joints morning stiffness, swelling and pain can be significantly relieved, joint activities have improved, and the patient’s self-care ability has partially recovered. Therefore, the biggest difference between “Yunke” and conventional drugs is that “Yunke” can not only control the development of the disease and prevent further damage to the bone and joint structure, but also repair the broken bones and restore the function of the damaged joints, so that the disease can be partially reversed. The shortcoming of “Yunke” is that the efficiency can only reach 80%, and some patients are not effective, as in the case of 131 iodine treatment for hyperthyroidism, which is mainly due to the individual differences in sensitivity and the adequacy of the dosage of the drug. Nevertheless, “Yunke” still opens a new way for the application of radiopharmaceuticals in the treatment of patients with rheumatoid arthritis. If patients with rheumatoid arthritis can use YUNKE as early as possible, they can stop the development and deterioration of the disease, and delay and avoid disability.